| Systematic (IUPAC) name | |
|---|---|
| 3-(cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide | |
| Clinical data | |
| Trade names | Daxas, Daliresp |
| AHFS/Drugs.com | Consumer Drug Information |
| MedlinePlus | a611034 |
| Licence data | EMA:Link, US FDA:link |
| Pregnancy cat. | C(US) |
| Legal status | POM (UK) ℞-only (US) |
| Routes | Oral |
| Identifiers | |
| CAS number | 162401-32-3 |
| ATC code | R03DX07 |
| PubChem | CID 158787 |
| ChemSpider | 139677 |
| UNII | 0P6C6ZOP5U |
| ChEMBL | CHEMBL193240 |
| Chemical data | |
| Formula | C17H14Cl2F2N2O3 |
| Mol. mass | 403.207 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| |
|
Roflumilast (trade names Daxas, Daliresp) is a drug which acts as a selective, long-acting inhibitor of the enzyme PDE-4. It has antiinflammatory effects and is under development as an orally administered drug for the treatment of inflammatory conditions of the lungs such as asthma, and chronic obstructive pulmonary disease (COPD).[1][2][3][4] While roflumilast was found to be effective in clinical trials, it produced several dose-limiting side effects including nausea, diarrhoea and headache, and development is continuing in an attempt to minimise the incidence of side effects while retaining clinical efficacy.[5]
In June 2010, Daxas was approved in the EU for severe COPD associated with chronic bronchitis.[6] In March 2011, Daliresp gained FDA approval in the US for reducing COPD exacerbations.[7]
Chemical synthesis:[8]
|
||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||
| This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)